RTTNews | Apr 29, 2021 10:28AM EDT

10:28 Thursday, April 29, 2021 (RTTNews.com) - Cara Therapeutics, Inc. (CARA) shares are sliding more than 42 percent on Thursday morning trade after the company said its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA failed to meet the primary endpoint of worst-itch NRS change baseline for the treatment of moderate-to-severe pruritus in mild-to-severe atopic dermatitis patients.

The shares of the clinical-stage biopharmaceutical company are currently at $14.90, down 42.19 percent from the previous close of us close of 5.79 on a volume of 4,797,887. For the 52-week period, the shares have traded in a range of $12.30-$29.65 on average volume of 951,022.

The Phase 2 trial had enrolled 401 patients at multiple clinical sites across the United States and was well tolerated.

Read the original article on RTTNews ( https://www.rttnews.com/3189915/stock-alert-cara-therapeutics-down-42-as-its-korsuva-trial-fails-to-meet-primary-endpoint.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved